Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/31707430
Journal: https://link.springer.com/article/10.1007%2Fs00259-019-04567-2